| 0.51 Data as of May 21 |  +0.05 / +10.87%Today’s Change | 0.43 Today|||52-Week Range 2.32 | -29.17% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $53.3M |
Company Description
Cytomedix, Inc. is a regenerative therapy company, harnessing the body's own capacity to heal itself. The company develops and commercializes innovative autologous therapies that promote healing by harnessing the innate regenerative capacity of platelets and adult stem cells. It currently has a growing commercial operation, and a robust clinical pipeline seeking to exploit large market opportunities with unmet medical needs. Cytomedix current commercial offerings are centered rich plasma platform technology, and primarily include the angel whole blood separation system and the autologel system. These products primarily address the areas of wound care, and support of healing and recovery following orthopedic procedures. The company was founded on April 29, 1998 and is headquartered in Gaithersburg, MD.
Employees
Shareholders
| Individual stakeholders | 28.09% |
| Other institutional | 0.12% |
| Mutual fund holders | 0.02% |
Top Executives
| David Emerson Jorden, MBA, CPA | Executive Chairman & Head-Investor Relations |
| Martin P. Rosendale | Chief Executive Officer & Director |
| Edward L. Field, MBA | Chief Operating Officer & Executive Vice President |
| Steven A. Shallcross, MBA, CPA | CFO, Secretary, Treasurer & Executive VP |
| Peter A. Clausen, PhD | Vice President-Business Development |
.
